Switch theme
Sign up to access all valuation multiples
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
1995
291
LTM Revenue $89.3M
LTM EBITDA -$45.9M
$105M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pulmonx has a last 12-month revenue (LTM) of $89.3M and a last 12-month EBITDA of -$45.9M.
In the most recent fiscal year, Pulmonx achieved revenue of $83.8M and an EBITDA of -$50.9M.
Pulmonx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pulmonx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $89.3M | XXX | $83.8M | XXX | XXX | XXX |
| Gross Profit | $66.0M | XXX | $62.0M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | -$45.9M | XXX | -$50.9M | XXX | XXX | XXX |
| EBITDA Margin | -51% | XXX | -61% | XXX | XXX | XXX |
| EBIT | -$59.6M | XXX | -$57.7M | XXX | XXX | XXX |
| EBIT Margin | -67% | XXX | -69% | XXX | XXX | XXX |
| Net Profit | -$58.6M | XXX | -$56.4M | XXX | XXX | XXX |
| Net Margin | -66% | XXX | -67% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pulmonx's stock price is $3.
Pulmonx has current market cap of $137M, and EV of $105M.
See Pulmonx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $105M | $137M | XXX | XXX | XXX | XXX | $-1.48 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pulmonx has market cap of $137M and EV of $105M.
Pulmonx's trades at 1.3x EV/Revenue multiple, and -2.1x EV/EBITDA.
Equity research analysts estimate Pulmonx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pulmonx has a P/E ratio of -2.3x.
See valuation multiples for Pulmonx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $137M | XXX | $137M | XXX | XXX | XXX |
| EV (current) | $105M | XXX | $105M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | -2.1x | XXX | XXX | XXX |
| EV/EBIT | -1.8x | XXX | -1.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.3x | XXX | -2.4x | XXX | XXX | XXX |
| EV/FCF | -4.2x | XXX | -3.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPulmonx's last 12 month revenue growth is 17%
Pulmonx's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Pulmonx's rule of 40 is -64% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pulmonx's rule of X is -9% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pulmonx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | -51% | XXX | -61% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -64% | XXX | -44% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -9% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 143% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pulmonx acquired XXX companies to date.
Last acquisition by Pulmonx was XXXXXXXX, XXXXX XXXXX XXXXXX . Pulmonx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pulmonx founded? | Pulmonx was founded in 1995. |
| Where is Pulmonx headquartered? | Pulmonx is headquartered in United States of America. |
| How many employees does Pulmonx have? | As of today, Pulmonx has 291 employees. |
| Who is the CEO of Pulmonx? | Pulmonx's CEO is Mr. Steven S. Williamson. |
| Is Pulmonx publicy listed? | Yes, Pulmonx is a public company listed on NAS. |
| What is the stock symbol of Pulmonx? | Pulmonx trades under LUNG ticker. |
| When did Pulmonx go public? | Pulmonx went public in 2020. |
| Who are competitors of Pulmonx? | Similar companies to Pulmonx include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Pulmonx? | Pulmonx's current market cap is $137M |
| What is the current revenue of Pulmonx? | Pulmonx's last 12 months revenue is $89.3M. |
| What is the current revenue growth of Pulmonx? | Pulmonx revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Pulmonx? | Current revenue multiple of Pulmonx is 1.2x. |
| Is Pulmonx profitable? | Yes, Pulmonx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pulmonx? | Pulmonx's last 12 months EBITDA is -$45.9M. |
| What is Pulmonx's EBITDA margin? | Pulmonx's last 12 months EBITDA margin is -51%. |
| What is the current EV/EBITDA multiple of Pulmonx? | Current EBITDA multiple of Pulmonx is -2.3x. |
| What is the current FCF of Pulmonx? | Pulmonx's last 12 months FCF is -$25.1M. |
| What is Pulmonx's FCF margin? | Pulmonx's last 12 months FCF margin is -28%. |
| What is the current EV/FCF multiple of Pulmonx? | Current FCF multiple of Pulmonx is -4.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
